Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

The funds were awarded to Han Xiao, a scientist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories.

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

From Your Site Articles
Rice University's SynthX Center, a collaborative lab focused on cancer treatments, named its inaugural seed grant recipients. Photo via Getty Images

3 Houston cancer-focused research projects receive seed grants from new innovative initiative

funding the future

Three groundbreaking projects have just received seed grants from a new Houston-based source.

This spring, Rice University launched its Synthesis X Center with the goal of fostering the growth of cancer technologies and medications. Now, the SynthX, as it is known, and Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center have announced joint awards of grants to promising teams, all of which have principals at either Rice or Baylor.

The teams include:

  • A project from Drs. Pabel Miah of Baylor and Lei Li of Rice that involves the development and optimization of high-resolution imaging technology that’s intended for use in removing breast cancer from patients. The researchers combine ultrasound with photoacoustic technology to produce real-time imaging that allows surgeons to spot hard-to-locate tumors. This could reduce or eliminate tumor localization procedures which are invasive and costly.
  • A leukemia treatment profiting from molecular jackhammers, a type of molecule invented in the Rice University lab of Dr. James Tour. He’s joined in the project by Drs. Xin Li and Yongcheng Song, both of Baylor. Molecular jackhammers vibrate more than a trillion times per second when activated by a specific light frequency. Doing this can kill nearby cancer cells. The new treatment is intended to disrupt the activity of a transcription protein called ENL that helps fuel the growth of leukemia cells in several acute forms of the disease.
  • A project that could discover how to inspire cancer cells to kill themselves, using a cancer-associated enzyme called lysine demethylase 4A. Baylor’s Dr. Ruhee Dere and Rice’s Dr. Anna Karin-Gustavsson are studying the KDM4A with the process of apoptosis, or programmed cell death, in mind for the aberrant cells.

The seed grants are managed by Rice’s office for Educational and Research Initiatives for Collaborative Health (ENRICH). Each of the three grants is intended to last two years and includes funds of up to $80,000.

The goal is to allow research teams to collect preliminary data that can be used to apply for more substantial grants from bodies like the Cancer Prevention and Research Institute of Texas (CPRIT) or the National Institute of Health (NIH).

Three quarters of the funds will be provided in the first year. Teams that produce grant submissions with multiple principal investigators in that first year will be eligible to collect the additional quarter.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

The NIH grant goes toward TransplantAI's work developing more precise models for heart and lung transplantation. Photo via Getty Images

Houston health tech company scores $2.2M grant to use AI to make organ transplants smarter, more successful

future of medicine

The National Institute of Health has bestowed a Houston medtech company with a $2.2 million Fast-Track to Phase 2 award. InformAI will use the money for the product development and commercialization of its AI-enabled organ transplant informatics platform.

Last year, InformAI CEO Jim Havelka told InnovationMap, “A lot of organs are harvested and discarded.”

TransplantAI solves that problem, as well as organ scarcity and inefficiency in allocation of the precious resource.

How does it work? Machine learning and deep learning from a million donor transplants informs the AI, which determines who is the best recipient for each available organ using more than 500 clinical parameters. Organ transplant centers and organ procurement organizations (OPOs) will be able to use the product to make a decision on how to allocate each organ in real time. Ultimately, the tool will service 250 transplant centers and 56 OPOs around the United States.

The NIH grant goes toward developing more precise models for heart and lung transplantation (kidney and liver algorithms are further along in development thanks to a previous award from the National Science Foundation), as well as Phase 2 efforts to fully commercialize TransplantAI.

"There is an urgent need for improved and integrated predictive clinical insights in solid organ transplantation, such as for real-time assessment of waitlist mortality and the likelihood of successful post-transplantation outcomes," according to the grant’s lead clinical investigator, Abbas Rana, associate professor of surgery at Baylor College of Medicine.

“This information is essential for healthcare teams and patients to make informed decisions, particularly in complex cases where expanded criteria allocation decisions are being considered," Rana continues. "Currently, the separation of donor and recipient data into different systems requires clinical teams to conduct manual, parallel reviews for pairing assessments. Our team, along with those at other leading transplant centers nationwide, receives hundreds of organ-recipient match offers weekly.”

Organ transplantation is moving into the future, and Transplant AI is at the forefront.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-based HPE wins $931M contract to upgrade military data centers

defense data centers

Hewlett Packard Enterprise (HPE), based in Spring, Texas, which provides AI, cloud, and networking products and services, has received a $931 million contract to modernize data centers run by the federal Defense Information Systems Agency.

HPE says it will supply distributed hybrid multicloud technology to the federal agency, which provides combat support for U.S. troops. The project will feature HPE’s Private Cloud Enterprise and GreenLake offerings. It will allow DISA to scale and accelerate communications, improve AI and data analytics, boost IT efficiencies, reduce costs and more, according to a news release from HPE.

The contract comes after the completion of HPE’s test of distributed hybrid multicloud technology at Defense Information Systems Agency (DISA) data centers in Mechanicsburg, Pennsylvania, and Ogden, Utah. This technology is aimed at managing DISA’s IT infrastructure and resources across public and private clouds through one hybrid multicloud platform, according to Data Center Dynamics.

Fidelma Russo, executive vice president and general manager of hybrid cloud at HPE, said in a news release that the project will enable DISA to “deliver innovative, future-ready managed services to the agencies it supports that are operating across the globe.”

The platform being developed for DISA “is designed to mirror the look and feel of a public cloud, replicating many of the key features” offered by cloud computing businesses such as Amazon Web Services (AWS), Microsoft Azure and Google Cloud Platform, according to The Register.

In the 1990s, DISA consolidated 194 data centers into 16. According to The Register, these are the U.S. military’s most sensitive data centers.

More recently, in 2024, the Fort Meade, Maryland-based agency laid out a five-year strategy to “simplify the network globally with large-scale adoption of command IT environments,” according to Data Center Dynamics.

Astros and Rockets launch new streaming service for Houston sports fans

Sports Talk

Houston sports fans now have a way to watch their favorite teams without a cable or satellite subscription. Launched December 3, the Space City Home Network’s SCHN+ service allows consumers to watch the Houston Astros and Houston Rockets via iOS, Apple TV, Android, Amazon Fire TV, or web browser.

A subscription to SCHN+ allows sports fans to watch all Astros and Rockets games, as well as behind-the-scenes features and other on-demand content. It’s priced at $19.99 per month or $199.99 annually (plus tax). People who watch Space City Network Network via their existing cable or satellite service will be able to access SCHN+ at no additional charge.

As the Houston Chronicle notes, the Astros and Rockets were the only MLB and NBA teams not to offer a direct-to-consumer streaming option.

“We’re thrilled to offer another great option to ensure fans have access to watch games, and the SCHN+ streaming app makes it easier than ever to cheer on the Rockets,” Rockets alternate governor Patrick Fertitta said in a statement.

“Providing fans with a convenient way to watch their favorite teams, along with our network’s award-winning programming, was an essential addition. This season feels special, and we’re committed to exploring new ways to elevate our broadcasts for Rockets fans to enjoy.”

Astros owner Jim Crane echoed Feritta’s comments, adding, “Providing fans options on how they view our games is important as we continue to grow the game – we want to make it accessible to as large an audience as possible. We are looking forward to the 2026 season and more Astros fans watching our players compete for another championship.”

SCHN+ is available to customers in Texas; Louisiana; Arkansas; Oklahoma; and the following counties in New Mexico: Dona Ana, Eddy, Lea, Chaves, Roosevelt, Curry, Quay, Union, and Debaca. Fans outside these areas will need to subscribe to the NBA and MLB out-of-market services.

---

This article originally appeared on CultureMap.com.

Rice University researchers unveil new model that could sharpen MRI scans

MRI innovation

Researchers at Rice University, in collaboration with Oak Ridge National Laboratory, have developed a new model that could lead to sharper imaging and safer diagnostics using magnetic resonance imaging, or MRI.

In a study recently published in The Journal of Chemical Physics, the team of researchers showed how they used the Fokker-Planck equation to better understand how water molecules respond to contrast agents in a process known as “relaxation.” Previous models only approximated how water molecules relaxed around contrasting agents. However, through this new model, known as the NMR eigenmodes framework, the research team has uncovered the “full physical equations” to explain the process.

“The concept is similar to how a musical chord consists of many notes,” Thiago Pinheiro, the study’s first author, a Rice doctoral graduate in chemical and biomolecular engineering and postdoctoral researcher in the chemical sciences division at Oak Ridge National Laboratory, said in a news release. “Previous models only captured one or two notes, while ours picks up the full harmony.”

According to Rice, the findings could lead to the development and application of new contrast agents for clearer MRIs in medicine and materials science. Beyond MRIs, the NMR relaxation method could also be applied to other areas like battery design and subsurface fluid flow.

“In the present paper, we developed a comprehensive theory to interpret those previous molecular dynamics simulations and experimental findings,” Dilipkumar Asthagiri, a senior computational biomedical scientist in the National Center for Computational Sciences at Oak Ridge National Laboratory, said in the release. ”The theory, however, is general and can be used to understand NMR relaxation in liquids broadly.”

The team has also made its code available as open source to encourage its adoption and further development by the broader scientific community.

“By better modeling the physics of nuclear magnetic resonance relaxation in liquids, we gain a tool that doesn’t just predict but also explains the phenomenon,” Walter Chapman, a professor of chemical and biomolecular engineering at Rice, added in the release. “That is crucial when lives and technologies depend on accurate scientific understanding.”

The study was backed by The Ken Kennedy Institute, Rice Creative Ventures Fund, Robert A. Welch Foundation and Oak Ridge Leadership Computing Facility at Oak Ridge National Laboratory.

View All Listings